Antidepressant profile in rodents of SR 58611A, a new selective agonist for atypical beta-adrenoceptors

European Journal of Pharmacology
J SimiandP Soubrié

Abstract

beta 2-Adrenoceptor agonists possess antidepressant-like activity in animals and man, but their peripheral side-effects prevent their therapeutic use. Atypical beta-adrenoceptors have not been demonstrated in the central nervous system, but are known to exist in peripheral tissues such as the rat colon. We have now studied the antidepressant-like effects in rodents of a new selective atypical beta-adrenoceptor agonist, SR 58611A. SR 58611A was active with minimal effective doses of 0.1-0.3 mg kg-1 i.p. in several models (antagonism of the hypothermia induced by apomorphine and reserpine; potentiation of the toxicity produced by yohimbine; reversal of learned helplessness), but was inactive in the tests of reserpine-induced ptosis and behavioural despair. The antidepressant-like effect of SR 58611A was not antagonised by selective beta 1- or beta 2-adrenoceptor antagonists, but was blocked by high doses of the non-selective beta-adrenoceptor antagonists, propranolol and alprenolol. Unlike beta 2-adrenoceptor agonists, SR 58611A did not reduce locomotor activity or increase water intake at doses up to 10 mg kg-1. Therefore, SR 58611A may represent the prototype of a new class of antidepressant compounds.

References

Mar 1, 1978·Pharmacological Research Communications·H F Simon
Oct 8, 1977·Lancet·D WidlöcherP Simon
Nov 23, 1979·European Journal of Pharmacology·M SoutoP Simon
Oct 1, 1990·British Journal of Clinical Pharmacology·A A ConnacherR T Jung
Sep 8, 1989·Science·L J EmorineA D Strosberg
Dec 1, 1985·Scandinavian Journal of Gastroenterology·E LyrenäsG Dotevall
Jan 1, 1987·Pharmacology, Biochemistry, and Behavior·H FrancesP Simon
Jul 1, 1987·British Journal of Pharmacology·R A Bond, D E Clarke
Feb 1, 1988·Biological Psychiatry·P GiralP Simon
Apr 1, 1980·The British Journal of Psychiatry : the Journal of Mental Science·Y LecrubierD Widlocher

Citations

Jan 1, 1995·Journal of Neural Transmission. General Section·M PonceletG Le Fur
Apr 1, 1995·Brain Research. Molecular Brain Research·M RodriguezD Shire
Dec 23, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Ming GuoDuo Chen
Apr 27, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jeanne StemmelinGuy Griebel
Nov 1, 1995·British Journal of Pharmacology·Roger J SummersB A Evans
Aug 16, 2008·The Journal of Clinical Investigation·V Arvydas SkeberdisRodolphe Fischmeister
Jun 2, 2007·Biological & Pharmaceutical Bulletin·K Ohkura
Feb 19, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Dhanisha J JhaveriPerry F Bartlett
Jul 2, 2005·Expert Opinion on Investigational Drugs·R L Dow
Mar 10, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Gastón ApablazaJaime Mella
Jan 1, 1996·The Journal of Clinical Psychiatry·P A Newhouse
Apr 19, 2019·Cells·Giorgia Schena, Michael J Caplan
Nov 1, 1993·Medicinal Research Reviews·J R Arch, A J Kaumann
Oct 31, 2003·Drugs in R&D
Aug 28, 2004·CNS Drugs·Fokko J BoskerJakob Korf
Mar 18, 2011·Expert Opinion on Therapeutic Patents·Maria Grazia Perrone, Antonio Scilimati

Related Concepts

Amibegron
Adrenergic beta-Agonists
Adrenergic beta-Antagonists
Proventil
Aptina
Metazoa
Thymoleptics
Behavior, Animal
Planipart
Tofranil

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.